Status: Recruiting
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).
Participants needed: 16
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Aligos TherapeuticsUpdated: Feb 4, 2026Locations: 1
Eligibility criteria
Male and Female between 18 and 75 years old [+10]
Subjects with any current or previous illness that, in the opinion of the Invest... [+19]